Tags

Type your tag names separated by a space and hit enter

Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast.
Ann Allergy Asthma Immunol. 2006 Jul; 97(1):98-104.AA

Abstract

BACKGROUND

Leukotriene modifiers have been shown to protect against exercise-induced bronchoconstriction (EIB) with repeated, chronic dosing.

OBJECTIVE

To study the onset and duration of protection against EIB after a single dose of montelukast, a leukotriene receptor antagonist.

METHODS

In this randomized, crossover, double-blind study, 51 adult asthma patients with EIB (> or = 20% postexercise decrease in forced expiratory volume in 1 second [FEV1]) received a single oral dose of montelukast (10 mg), or placebo followed by exercise challenge 2, 12, and 24 hours after dosing. The primary end point was maximum percentage decrease in FEV1 from preexercise baseline during 60 minutes after the 2-hour challenge.

RESULTS

At 2, 12, and 24 hours after dosing, the maximum decrease in FEV1 was 10.8% +/- 7.9%, 8.4% +/- 7.5%, and 8.3% +/- 7.3% for montelukast and 22.3% +/- 13.1%, 16.1% +/- 10.2%, and 16.9% +/- 11.7% for placebo, respectively (P < or = .001 at each time point). Postexercise recovery was quicker with montelukast than with placebo (P < or = .001); mean (95% confidence interval) differences were -26.8 minutes (-35.1 to -18.4 minutes), -16.0 minutes (-22.9 to -9.2 minutes), and -17.4 minutes (-24.9 to -9.9 minutes) at the 3 time points, respectively. At all time points, area under the curve for percentage decrease in FEV1 during 60 minutes after exercise was smaller after montelukast (P < or = .001); montelukast protected more patients against EIB (P < or = .001). Fewer patients required postexercise beta-agonist rescue at 2 hours after dosing with montelukast (P = .03).

CONCLUSION

Montelukast provided significant protection against EIB as soon as 2 hours after a single oral dose, with persistent benefit up to 24 hours.

Authors+Show Affiliations

Colorado Allergy and Asthma Centers, PC, Denver, Colorado 80230, USA. ds.pearlman@coloradoallergy.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16892789

Citation

Pearlman, David S., et al. "Onset and Duration of Protection Against Exercise-induced Bronchoconstriction By a Single Oral Dose of Montelukast." Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, vol. 97, no. 1, 2006, pp. 98-104.
Pearlman DS, van Adelsberg J, Philip G, et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol. 2006;97(1):98-104.
Pearlman, D. S., van Adelsberg, J., Philip, G., Tilles, S. A., Busse, W., Hendeles, L., Loeys, T., Dass, S. B., & Reiss, T. F. (2006). Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 97(1), 98-104.
Pearlman DS, et al. Onset and Duration of Protection Against Exercise-induced Bronchoconstriction By a Single Oral Dose of Montelukast. Ann Allergy Asthma Immunol. 2006;97(1):98-104. PubMed PMID: 16892789.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. AU - Pearlman,David S, AU - van Adelsberg,Janet, AU - Philip,George, AU - Tilles,Stephen A, AU - Busse,William, AU - Hendeles,Leslie, AU - Loeys,Thomas, AU - Dass,S Balachandra, AU - Reiss,Theodore F, PY - 2006/8/9/pubmed PY - 2006/9/7/medline PY - 2006/8/9/entrez SP - 98 EP - 104 JF - Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology JO - Ann Allergy Asthma Immunol VL - 97 IS - 1 N2 - BACKGROUND: Leukotriene modifiers have been shown to protect against exercise-induced bronchoconstriction (EIB) with repeated, chronic dosing. OBJECTIVE: To study the onset and duration of protection against EIB after a single dose of montelukast, a leukotriene receptor antagonist. METHODS: In this randomized, crossover, double-blind study, 51 adult asthma patients with EIB (> or = 20% postexercise decrease in forced expiratory volume in 1 second [FEV1]) received a single oral dose of montelukast (10 mg), or placebo followed by exercise challenge 2, 12, and 24 hours after dosing. The primary end point was maximum percentage decrease in FEV1 from preexercise baseline during 60 minutes after the 2-hour challenge. RESULTS: At 2, 12, and 24 hours after dosing, the maximum decrease in FEV1 was 10.8% +/- 7.9%, 8.4% +/- 7.5%, and 8.3% +/- 7.3% for montelukast and 22.3% +/- 13.1%, 16.1% +/- 10.2%, and 16.9% +/- 11.7% for placebo, respectively (P < or = .001 at each time point). Postexercise recovery was quicker with montelukast than with placebo (P < or = .001); mean (95% confidence interval) differences were -26.8 minutes (-35.1 to -18.4 minutes), -16.0 minutes (-22.9 to -9.2 minutes), and -17.4 minutes (-24.9 to -9.9 minutes) at the 3 time points, respectively. At all time points, area under the curve for percentage decrease in FEV1 during 60 minutes after exercise was smaller after montelukast (P < or = .001); montelukast protected more patients against EIB (P < or = .001). Fewer patients required postexercise beta-agonist rescue at 2 hours after dosing with montelukast (P = .03). CONCLUSION: Montelukast provided significant protection against EIB as soon as 2 hours after a single oral dose, with persistent benefit up to 24 hours. SN - 1081-1206 UR - https://www.unboundmedicine.com/medline/citation/16892789/Onset_and_duration_of_protection_against_exercise_induced_bronchoconstriction_by_a_single_oral_dose_of_montelukast_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1081-1206(10)61377-4 DB - PRIME DP - Unbound Medicine ER -